Volociximab in Combination With DTIC in Patients With Metastatic Melanoma Not Previously Treated With Chemotherapy
Status:
Completed
Trial end date:
2006-03-01
Target enrollment:
Participant gender:
Summary
This clinical trial is being conducted to determine tumor response and preliminary safety of
a monoclonal antibody that specifically binds to a cell surface receptor (α5β1 integrin) that
is required for the establishment of new blood vessels during tumor growth, a process known
as angiogenesis.